Aceto Corporation | Exhibit 99.2 |
UNAUDITED PRO FORMA FINANCIAL INFORMATION (in thousands)
On December 31, 2010, Aceto Corporation (“Aceto” or the “Company”) acquired certain assets of Rising Pharmaceuticals, Inc. (“Rising”), a New Jersey based company that markets and distributes generic prescription and over the counter pharmaceutical products to leading wholesalers, chain drug stores, distributors, mass market merchandisers and others under its own label, throughout the United States. The purchase price was approximately $73,317 which was comprised of the issuance of 1,000 shares of Aceto common stock, valued at $9,000, cash payment of approximately $58,817 and approximately $5,500 liability due to Rising to satisfy bulk sales tax obligation. The purchase agreement also calls for $8,000 of deferred consideration to be paid by Aceto over a four year period. In addition, the agreement provides for the payment of additional contingent consideration equal to one-half of the three year cumulative Rising earnings before interest, taxes, deprecation and amortization in excess of $32,100, up to a maximum of $6,000. As of December 31, 2010, the Company had accrued $850 related to this contingent consideration.
The following unaudited pro forma combined financial statements reflect the acquisition of certain assets of Rising using the purchase method of accounting. The acquisition has been accounted for in conformity with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 805, Business Combinations (“ASC 805”). The pro forma adjustments are based upon available information and assumptions that we believe are reasonable. The pro forma adjustments are preliminary and have been prepared to illustrate the estimated effect of the acquisition. Differences between these preliminary estimates and the final acquisition accounting will occur and these differences could have a material impact on the accompanying unaudited pro forma combined financial statements and the combined companies’ future results of operations and financial position. The unaudited pro forma combined financial statements do not purport to be indicative of the operating results or financial position that would have been achieved had the acquisition taken place on the date indicated or the results that may be obtained in the future.
The unaudited pro forma combined balance sheet as of September 30, 2010 is presented as if our acquisition of certain assets of Rising had occurred on September 30, 2010.
The unaudited pro forma combined consolidated statements of income for the year ended June 30, 2010 and the three months ended September 30, 2010 illustrate the effect of the Rising acquisition as if it had occurred on July 1, 2009. The unaudited pro forma combined consolidated statement of income for the year ended June 30, 2010 combines the historical audited statement of income of Aceto for the year ended June 30, 2010 and Rising’s historical unaudited statement of income for the twelve months ended June 30, 2010. Rising’s fiscal year ended on December 31 and thus, the twelve month period was compiled by combining each quarterly statement of income for each period from July 1, 2009 to June 30, 2010. The unaudited pro forma combined consolidated statement of income for the three months ended September 30, 2010 combines the historical unaudited statement of income of both Aceto and Rising for the three months ended September 30, 2010. The historical consolidated financial information has been adjusted to give effect to pro forma events that are (i) directly attributable to the acquisition, (ii) factually supportable, and (iii) with respect to the statements of income, expected to have a continuing impact on the combined results of the companies. These unaudited pro forma condensed combined financial statements are prepared by management for informational purposes only in accordance with Article 11 of Securities and Exchange Commission Regulation S-X and are not necessarily indicative of future results or of actual results that would have been achieved had the acquisition been consummated as of the dates presented, and should not be taken as representative of future consolidated operating results of Aceto. The unaudited pro forma combined financial statements do not reflect any operating efficiencies and/or cost savings that we may achieve, or any additional expenses or costs of integration that we may incur, with respect to the combined companies as such adjustments are not factually supportable at this point in time. The assumptions used to prepare the pro forma financial information are contained in the notes to the unaudited pro forma combined financial statements, and such assumptions should be reviewed in their entirety.
The unaudited pro forma combined financial statements have been developed from and should be read in conjunction with (i) the historical audited consolidated financial statements for the year ended June 30, 2010 and notes thereto of Aceto contained in its Annual Report on Form 10-K , (ii) the historical unaudited consolidated financial statements and notes thereto of Aceto contained in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2010 and (iii) historical audited financial statements and notes thereto of Rising, included in exhibit 99.1 of this Current Report on Form 8-K.
ACETO CORPORATION
Unaudited Pro Forma Combined Balance Sheet
September 30, 2010
Aceto September 30, 2010 Historical | Rising September 30, 2010 Historical | Pro Forma Adjustments | Pro Forma Combined | |||||||||||||
ASSETS | ||||||||||||||||
Current assets: | ||||||||||||||||
Cash and cash equivalents | $ | 40,113 | $ | 8,926 | $ | (8,817 | ) | (A) | $ | 40,222 | ||||||
Investments | 402 | - | - | 402 | ||||||||||||
Trade receivables, less allowance for doubtful accounts | 58,354 | 10,669 | - | 69,023 | ||||||||||||
Other receivables | 13,087 | - | - | 13,087 | ||||||||||||
Inventory | 77,050 | 2,775 | 258 | (B) | 80,083 | |||||||||||
Prepaid expenses and other current assets | 2,155 | 1,052 | 66 | (C) | 3,273 | |||||||||||
Deferred income tax asset, net | 1,750 | - | - | 1,750 | ||||||||||||
Total current assets | 192,911 | 23,422 | (8,493 | ) | 207,840 | |||||||||||
Property and equipment, net | 7,183 | 600 | - | 7,783 | ||||||||||||
Property held for sale | 3,752 | - | - | 3,752 | ||||||||||||
Goodwill | 1,830 | 821 | 30,942 | (D) | 33,593 | |||||||||||
Intangible assets, net | 11,834 | - | 43,200 | (E) | 55,034 | |||||||||||
Deferred income tax asset, net | 2,337 | - | - | 2,337 | ||||||||||||
Other assets | 9,814 | 30 | - | 9,844 | ||||||||||||
TOTAL ASSETS | $ | 229,661 | $ | 24,873 | $ | 65,649 | $ | 320,183 | ||||||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||||||||||
Current liabilities: | ||||||||||||||||
Accounts payable | $ | 30,135 | $ | 976 | - | $ | 31,111 | |||||||||
Short-term bank loans | 5,000 | - | 6,000 | (A) | 11,000 | |||||||||||
Accrued expenses | 28,306 | 5,900 | 647 | (F) | 54,499 | |||||||||||
2,600 | (G) | |||||||||||||||
11,546 | (H) | |||||||||||||||
5,500 | (I) | |||||||||||||||
Deferred income tax liability | 897 | - | - | 897 | ||||||||||||
Total current liabilities | 64,338 | 6,876 | 26,293 | 97,507 | ||||||||||||
Long-term bank loans | 550 | - | 44,000 | (A) | 44,550 | |||||||||||
Long-term liabilities | 9,310 | - | 7,600 | (J) | 16,910 | |||||||||||
Environmental remediation liability | 7,539 | - | 7,539 | |||||||||||||
Deferred income tax liability | 44 | - | - | 44 | ||||||||||||
Total liabilities | 81,781 | 6,876 | 77,893 | 166,550 | ||||||||||||
Shareholders’ equity: | ||||||||||||||||
Common stock | 256 | 174 | 10 | (K) | 266 | |||||||||||
(174 | ) | (L) | ||||||||||||||
Capital in excess of par value | 53,776 | - | 8,990 | (K) | 62,766 | |||||||||||
Retained earnings | 89,755 | 18,570 | (647 | ) | (F) | 86,508 | ||||||||||
(2,600 | ) | (G) | ||||||||||||||
(18,570 | ) | (L) | ||||||||||||||
Treasury | (1,926 | ) | (747 | ) | 747 | (L) | (1,926 | ) | ||||||||
Accumulated other comprehensive income | 6,019 | - | - | 6,019 | ||||||||||||
Total shareholders’ equity | 147,880 | 17,997 | (12,244 | ) | 153,633 | |||||||||||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ | 229,661 | $ | 24,873 | $ | 65,649 | $ | 320,183 |
See the accompanying notes to the Pro Forma Combined Financial Statements
2
ACETO CORPORATION | ||||||||||||||||||
Unaudited Pro Forma Combined Statement of Income | ||||||||||||||||||
For The Year Ended June 30, 2010 | ||||||||||||||||||
(In thousands, except per share amounts) | ||||||||||||||||||
Aceto for the year ended | Rising | |||||||||||||||||
for the | ||||||||||||||||||
twelve months ended | ||||||||||||||||||
June 30, 2010 | June 30, 2010 | Pro Forma | Pro Forma | |||||||||||||||
Historical | Historical | Adjustments | Combined | |||||||||||||||
Net sales | $ | 346,631 | $ | 48,462 | $ | 395,093 | ||||||||||||
Cost of sales | 292,476 | 27,077 | 319,553 | |||||||||||||||
Gross profit | 54,155 | 21,385 | - | 75,540 | ||||||||||||||
Selling, general and administrative expenses | 44,717 | 8,457 | 4,321 | (M) | 57,495 | |||||||||||||
Operating income | 9,438 | 12,928 | (4,321 | ) | 18,045 | |||||||||||||
Other income (expense): | ||||||||||||||||||
Interest expense | (230 | ) | (6 | ) | (236 | ) | ||||||||||||
Interest and other income (expense), net | 995 | 31 | (1,750 | ) | (N) | |||||||||||||
(522 | ) | (O) | (1,246 | ) | ||||||||||||||
765 | 25 | (2,272 | ) | (1,482 | ) | |||||||||||||
Income before income taxes | 10,203 | 12,953 | (6,593 | ) | 16,563 | |||||||||||||
Income tax provision | 3,622 | 9 | 2,480 | (P) | 6,111 | |||||||||||||
Net income | $ | 6,581 | $ | 12,944 | $ | (9,073 | ) | $ | 10,452 | |||||||||
Net income per common share | $ | 0.26 | $ | 0.40 | ||||||||||||||
Diluted net income per common share | $ | 0.26 | $ | 0.40 | ||||||||||||||
Weighted average shares outstanding: | ||||||||||||||||||
Basic | 24,979 | 1,000 | ( K) | 25,979 | ||||||||||||||
Diluted | 25,224 | 1,000 | ( K) | 26,224 |
See the accompanying notes to the Pro Forma Combined Financial Statements
3
ACETO CORPORATION | |||||||||||||||||
Unaudited Pro Forma Combined Statement of Income | |||||||||||||||||
For The Three Months Ended September 30, 2010 | |||||||||||||||||
(In thousands, except per share amounts) | |||||||||||||||||
Aceto | Rising | ||||||||||||||||
for the | for the | ||||||||||||||||
three months ended | three months ended | ||||||||||||||||
September 30, 2010 | September 30, 2010 | Pro Forma | Pro Forma | ||||||||||||||
Historical | Historical | Adjustments | Combined | ||||||||||||||
Net sales | $ | 87,660 | $ | 12,382 | $ | 100,042 | |||||||||||
Cost of sales | 74,373 | 5,540 | 79,913 | ||||||||||||||
Gross profit | 13,287 | 6,842 | - | 20,129 | |||||||||||||
Selling, general and administrative expenses | 9,597 | 2,779 | 1,080 | (M) | 13,456 | ||||||||||||
Operating income | 3,690 | 4,063 | (1,080 | ) | 6,673 | ||||||||||||
Other income (expense): | |||||||||||||||||
Interest expense | (111 | ) | 6 | (105 | ) | ||||||||||||
Interest and other income (expense), net | 671 | 3 | (438) | (N) | |||||||||||||
(65) | (O) | 171 | |||||||||||||||
560 | 9 | (503 | ) | 66 | |||||||||||||
Income before income taxes | 4,250 | 4,072 | (1,583 | ) | 6,739 | ||||||||||||
Income tax provision | 1,453 | 17 | 971 | (P) | 2,441 | ||||||||||||
Net income | $ | 2,797 | $ | 4,055 | $ | (2,554 | ) | $ | 4,298 | ||||||||
Net income per common share | $ | 0.11 | $ | 0.16 | |||||||||||||
Diluted net income per common share | $ | 0.11 | $ | 0.16 | |||||||||||||
Weighted average shares outstanding: | |||||||||||||||||
Basic | 25,329 | 1,000 | ( K) | 26,329 | |||||||||||||
Diluted | 25,506 | 1,000 | ( K) | 26,506 |
See the accompanying notes to the Pro Forma Combined Financial Statements
4
ACETO CORPORATION
Notes to Unaudited Pro Forma Combined Financial Statements
(In thousands, except per share amounts)
1. Background and Basis of Pro Forma Presentation
On December 31, 2010, Aceto Corporation (“Aceto” or the “Company”) acquired certain assets of Rising Pharmaceuticals, Inc. (“Rising”), a New Jersey based company that markets and distributes generic prescription and over the counter pharmaceutical products to leading wholesalers, chain drug stores, distributors, mass market merchandisers and others under its own label, throughout the United States.
The unaudited pro forma combined financial information was prepared based on the historical financial statements of Aceto and Rising.
Our acquisition has been accounted for in conformity with ASC 805 and uses the fair value concepts defined in Accounting Standards Codification 820, Fair Value Measurements and Disclosures (“ASC 820-10”). ASC 805 requires, among other things, that most assets acquired and liabilities assumed in an acquisition be recognized at their fair values as of the acquisition date and requires that fair value be measured based on the principles in ASC 820-10. ASC 820-10 clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. ASC 820-10 also requires that a fair value measurement reflect the assumptions market participants would use in pricing an asset or liability based on the best information available.
2. Purchase Price Allocation
The acquisition is accounted for using the acquisition method of accounting. The total estimated purchase price is comprised of the following:
Cash paid at initial closing | $ | 58,817 | ||
Common stock issued | 9,000 | |||
Bulk sales tax obligation | 5,500 | |||
Estimated present value of deferred consideration | 6,750 | |||
Estimated present value of additional contingent consideration | 850 | |||
$ | 80,917 | |||
5
The following table summarizes the preliminary allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of December 31, 2010 as if the acquisition had occurred on September 30, 2010.
Cash and cash equivalents | $ | 8,926 | ||
Trade receivables | 10,669 | |||
Inventory | 3,033 | |||
Prepaid expenses and other current assets | 1,118 | |||
Property and equipment, net | 600 | |||
Goodwill | 31,763 | |||
Intangible assets | 43,200 | |||
Other assets | 30 | |||
Total assets acquired | 99,339 | |||
Accounts payable | 976 | |||
Accrued expenses | 17,446 | |||
Net assets acquired | $ | 80,917 | ||
3. Pro Forma Financial Statement Adjustments
The following pro forma adjustments are included in the Company’s unaudited pro forma combined financial statements:
A. | To reflect $58,817 of cash paid in connection with the acquisition of Rising, offset by the incurrence of $50,000 of bank borrowings used to finance the acquisition. |
B. | Adjustment to record a $258 step-up in the fair value of inventory. |
C. | To reflect purchase of continuum insurance policy. |
D. | To eliminate Rising’s historical goodwill of $821 and record the preliminary estimate of goodwill for our acquisition of Rising of $31,763. |
E. | To record the preliminary estimate of the fair value of intangible assets for our acquisition of Rising. The amortizable intangible assets acquired are comprised of the following: approximately $32,500 of product rights, amortizable over a period of seven to fourteen years; approximately $5,100 of license agreements, amortizable over six years; approximately $3,900 of customer relationships, amortizable over eleven years; and approximately $1,700 of trademarks, amortizable over a period of four years. |
F. | To reflect after tax impact of non-recurring acquisition-related transaction costs. |
G. | To reflect tax charge related to the repatriation of earnings from certain foreign subsidiaries to assist with the funding of the acquisition. |
H. | To reflect working capital adjustment calculated in accordance with the asset purchase agreement. |
I. | To reflect approximate $5,500 liability due to Rising to satisfy bulk sales tax obligation. |
6
J. | To reflect the fair value of deferred consideration of $6,750 to be paid by Aceto over a four year period and the fair value of additional contingent consideration of $850 equal to one-half of the three year cumulative Rising earnings before interest, taxes, deprecation and amortization in excess of $32,100, up to a maximum of $6,000. |
K. | To reflect 1,000 shares of Aceto common stock issued in connection with the acquisition of certain assets of Rising, valued at $9.00, the closing price of Aceto stock on the closing date. |
L. | To eliminate Rising's historical shareholders' equity. |
M. | Adjustment to record the amortization expense related to the amortizable intangible assets acquired. |
N. | To reflect increase in interest expense associated with bank borrowings to fund the acquisition. On December 31, 2010, we borrowed $10,000 of Revolving Loans and a Term Loan of $40,000. Both loans were utilized by us to partially finance payment of the purchase price for the Rising acquisition. The interest rate on both loans is at an Alternate Base Rate or 3.5% at December 31, 2010. Aceto may repay the Revolving Loan during the period ending December 31, 2015. The Term Loan is payable as to principal in twenty (20) consecutive quarterly installments, commencing March 31, 2011 and on each June 30, September 30 and December 31st thereafter. |
O. | To reflect interest expense associated with the discount of the deferred consideration and the contingent consideration. |
P. | Adjustment to record an income tax provision for Rising and pro forma adjustments using a 39% tax rate. Prior to the acquisition, Rising was an S Corporation and was not taxed at the Corporation level. |
The pro forma adjustments included in the income statements do not give effect to the impact on gross profit of the adjustment to increase inventory by approximately $258 to its estimated fair value and the impact of non-recurring acquisition-related transaction costs of approximately $1,060. The pro forma adjustments included in the income statements also do not give effect to the impact of the $2,600 tax charge related to the repatriation of earnings from certain foreign subsidiaries to assist with the funding of the acquisition.
7